Edward Seguine is the CEO of Clinical Ink, a pioneer in the development of electronic source record solutions for clinical research.  Prior to Clinical Ink, Mr. Seguine was the General Manager of Medidata’s Trial Planning product suite after serving as the CEO of Fast Track Systems before that company was acquired by Medidata.Mr. Seguine began his pharma career at Eli Lilly where he helped establish Lilly’s venture capital groups e.Lilly and Lilly Bioventures. Mr. Seguine has participated as an active board member and advisor for numerous start-up companies as well as CDISC.  In addition, he has actively collaborated with leading academic institutions (Tufts CSDD, MIT, Duke) to develop, publish and present research into novel approaches to improving clinical development.  Ed earned a BS in Finance from Brigham Young University, an MBA from Indiana University, and spent several years early in his career as the VP Finance of a start-up defense technology company. In this interview, Ed discusses the $7-10B industry of monitoring research sites for clinical trials, as well as the broader context and process of this dynamic and critical space including Meaningful Use.